Interview with Jürgen Fritze, Head of Medical Affairs, PKV
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Address: Gottfried-Hagen Str. 62
D-51105 Köln,Germany
Tel: +49 (0)2 21- 46 02 08 00
CEVEC focuses on the development of a platform expression technology based on specific human cell lines (CAP cell lines) and on the development of selected biopharmaceuticals. CEVEC was founded in 2001 by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work they had experienced a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors.
As part of the PKV – the German Association of Private Health Insurance – could you briefly introduce to our readers the German private health care system and its main…
Could you briefly introduce our readers the how the GPHF managed to improve health care in developing countries since its foundation in 1987? The former abbreviation of GPHF stood for…
You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France,…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here
